Unidad de Investigación Clínica de Cáncer de Próstata

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Cáncer de Próstata

David Olmos
David Olmos Jefe de Unidad de Investigación Clínica
T +34 (+34) 917 328 000 (Ext 2950)


  • Pedro P. Lopez-Casas

Becarios Post-doctorales

  • Carlo Cattrini
  • María Isabel Pacheco

Técnicos de Laboratorio

  • Mónica Balsells
  • Eva María Casas
  • Ylenia Cendón
  • Jenniffer Patricia Condo
  • Carles Moreno
  • Leticia Rivera
  • Alejandro Sanz

Prostate cancer remains a major health burden as over a million men around the world are annually diagnosed with prostate cancer. Up to 30% of them may develop metastatic prostate cancer, which is the advanced form of this disease, once it has spread outside the prostate and is no longer curable. This metastatic stage causes about 6,000 deaths every year in Spain alone, whilst in the US over 30,000 men succumb to the disease every year. In recent years, different subtypes of prostate cancer have been identified based on different genomic profiles. We believe that a better understanding of cancer biology, as well as an improved human prostate cancer taxonomy linked to clinical outcomes, could lead to improved patient outcomes through the application of tailored treatment strategies as opposed to the current one-fits-all approach. As an example of one of these clusters, 20-25% of all metastatic prostate cancers have aberrations in DNA repair genes; about half of these aberrations may correspond to inherited mutations.